MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

NCT05365659·PHASE1·Iksuda Therapeutics Ltd.·140 enrolled

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050·PHASE1 / PHASE2·City of Hope Medical Center·50 enrolled

BiopsyBiospecimen CollectionBone Marrow BiopsyComputed TomographyGlofitamab+4 more

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT05453396·PHASE2·University of Washington·40 enrolled

Loncastuximab Tesirine

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT05432635·PHASE1·City of Hope Medical Center·15 enrolled

Anti-CD19-CAR CMV-specific T-lymphocytesAutologous Hematopoietic Stem Cell TransplantationMulti-peptide CMV-Modified Vaccinia Ankara VaccineMyeloablative Conditioning

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363·PHASE1·Carna Biosciences, Inc.·120 enrolled

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

NCT05659732·PHASE1·PharmaEngine·32 enrolled

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

NCT05780034·PHASE1·Accutar Biotechnology Inc·60 enrolled

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

NCT06593145·PHASE1·FamiCordTx·6 enrolled

FCTX-CL19-1 (Tarcidomgen Kimleucel)

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019·PHASE1·Schrödinger, Inc.·98 enrolled

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

NCT05643742·PHASE1 / PHASE2·CRISPR Therapeutics AG·120 enrolled

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05724121·National Heart, Lung, and Blood Institute (NHLBI)·135 enrolled

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069·PHASE2·M.D. Anderson Cancer Center·30 enrolled

PirtobrutinibVenetoclax

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

NCT05643235·NA·Northwell Health·50 enrolled

Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)

A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

NCT05245656·PHASE2·Kim, Seok Jin·90 enrolled

RB/RBAC alternatingRB

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

NCT05506410·Zhengzhou University·100 enrolled

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

NCT05992597·PHASE2·Zhejiang Cancer Hospital·48 enrolled

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720·PHASE2·Genmab·496 enrolled

EpcoritamabLenalidomideIbrutinibRituximabCyclophosphamide+4 more

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

NCT05370430·PHASE1·PeproMene Bio, Inc.·36 enrolled

BAFFR-CAR T cells

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

NCT05255354·Adaptive Biotechnologies·300 enrolled

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731·PHASE1 / PHASE2·BeiGene·146 enrolled

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT05281809·PHASE2·John Lister·30 enrolled

Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022·PHASE1·Nurix Therapeutics, Inc.·572 enrolled

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

NCT05249959·PHASE2·Fondazione Italiana Linfomi - ETS·49 enrolled

Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

NCT05098613·PHASE1·University of Colorado, Denver·68 enrolled

CD19x22 CAR T Cells

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716·PHASE1 / PHASE2·BeOne Medicines·614 enrolled

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

NCT04883437·PHASE2·Emory University·49 enrolled

AcalabrutinibObinutuzumabQuality-of-Life AssessmentQuestionnaire Administration

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

NCT04626791·PHASE2·Academic and Community Cancer Research United·45 enrolled

AcalabrutinibBortezomibCyclophosphamideCytarabineDoxorubicin Hydrochloride+3 more

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT04491370·PHASE1 / PHASE2·New York Medical College·20 enrolled

Polatuzumab vedotin

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

NCT04775745·PHASE1·Newave Pharmaceutical Inc·60 enrolled

Avo In R/R And Previously Untreated MCL

NCT04855695·PHASE1 / PHASE2·Austin I Kim·72 enrolled

AcalabrutinibVenetoclaxObinutuzumab

← PreviousPage 3 of 41Next →